INmune Bio, Inc. (NASDAQ:INMB) Receives $22.80 Average Price Target from Brokerages

INmune Bio, Inc. (NASDAQ:INMB) has received a consensus rating of “Buy” from the six brokerages that are presently covering the stock, MarketBeat.com reports. Five investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokerages that have covered the stock in the last year is $22.80.

A number of research analysts recently commented on INMB shares. Rodman & Renshaw started coverage on INmune Bio in a report on Tuesday, January 28th. They issued a “buy” rating and a $23.00 price target for the company. RODMAN&RENSHAW upgraded INmune Bio to a “strong-buy” rating in a research note on Tuesday, January 28th. Scotiabank lifted their price target on shares of INmune Bio from $22.00 to $23.00 and gave the stock a “sector outperform” rating in a research note on Tuesday, February 11th. Finally, Maxim Group upped their price target on shares of INmune Bio from $22.00 to $30.00 and gave the company a “buy” rating in a report on Thursday, February 13th.

Institutional Trading of INmune Bio

A number of hedge funds and other institutional investors have recently modified their holdings of INMB. State Street Corp boosted its holdings in INmune Bio by 35.1% during the third quarter. State Street Corp now owns 226,428 shares of the company’s stock worth $1,220,000 after buying an additional 58,838 shares in the last quarter. Jane Street Group LLC acquired a new stake in INmune Bio during the 3rd quarter worth about $79,000. XTX Topco Ltd purchased a new position in INmune Bio during the third quarter valued at approximately $249,000. Barclays PLC grew its holdings in shares of INmune Bio by 601.9% during the 3rd quarter. Barclays PLC now owns 29,044 shares of the company’s stock valued at $157,000 after acquiring an additional 24,906 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in INmune Bio by 6.6% in the 3rd quarter. Geode Capital Management LLC now owns 344,466 shares of the company’s stock worth $1,857,000 after purchasing an additional 21,262 shares during the last quarter. Institutional investors own 12.72% of the company’s stock.

INmune Bio Stock Performance

INmune Bio stock opened at $7.27 on Friday. INmune Bio has a one year low of $4.32 and a one year high of $12.72. The stock’s 50 day moving average price is $8.44 and its 200 day moving average price is $6.46. The firm has a market capitalization of $166.70 million, a PE ratio of -3.33 and a beta of 1.86.

INmune Bio (NASDAQ:INMB) last posted its earnings results on Thursday, March 27th. The company reported ($0.40) EPS for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.14. On average, analysts forecast that INmune Bio will post -2.24 earnings per share for the current fiscal year.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.